CHANGE OF LIFE HAS RANGE OF SYMPTOMS, TREATMENTS
When it comes to menopause, one of the certainties is that it’s something all women, except those few who’ve had their ovaries removed prepuberty, will experience. Approximately 70 to 80 percent of...
View ArticleFDA approves first nonhormonal drug for hot flashes
Published July 01, 2013The Wall Street Journal The Food and Drug Administration Friday approved the first nonhormonal drug designed to treat hot flashes, one of the most bothersome symptoms of...
View ArticleNew Survey Sheds Light on Moms' Perspectives About ADHD Medications
Moms of Children Taking ADHD Prescription Medication Feel Like They Are Doing the Right Thing, Yet Challenges and Knowledge Gaps Remain Google...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory...
View ArticleFDA approves first nonhormonal drug for hot flashes
Published July 01, 2013The Wall Street Journal The Food and Drug Administration Friday approved the first nonhormonal drug designed to treat hot flashes, one of the most bothersome symptoms of...
View ArticleNew Survey Sheds Light on Moms' Perspectives About ADHD Medications
Moms of Children Taking ADHD Prescription Medication Feel Like They Are Doing the Right Thing, Yet Challenges and Knowledge Gaps Remain Google...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory...
View ArticleShionogi Inc. Announces Co-Promotion Agreement with Noven Pharmaceuticals For...
FLORHAM PARK, N.J., Jan. 13, 2014 /PRNewswire/ -- Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote Brisdelle™...
View ArticleSHIONOGI INC. ANNOUNCES CO-PROMOTION AGREEMENT WITH NOVEN PHARMACEUTICALS FOR...
(Source: Shionogi & Co Ltd) SHIONOGI INC. ANNOUNCES CO-PROMOTION AGREEMENT WITH NOVEN PHARMACEUTICALS FOR BRISDELLE™ (PAROXETINE) CAPSULES FLORHAM PARK, NJ (January 13, 2014) - Shionogi Inc. today...
View ArticleNoven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine)...
Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopausal Hot Flashes Download image Noven Pharmaceuticals, Inc....
View ArticleFDA approves first nonhormonal drug for hot flashes
Published July 01, 2013The Wall Street Journal The Food and Drug Administration Friday approved the first nonhormonal drug designed to treat hot flashes, one of the most bothersome symptoms of...
View ArticleNoven Pharmaceuticals, Inc. press release :Noven Enters Co-Promotion...
(Source: Hisamitsu Pharmaceutical Co Ltd) Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only...
View ArticleNew Survey Sheds Light on Moms' Perspectives About ADHD Medications
Moms of Children Taking ADHD Prescription Medication Feel Like They Are Doing the Right Thing, Yet Challenges and Knowledge Gaps Remain Google...
View ArticleNoven’s niche: The Miami company is key poducer of transdermal patches
At the Noven Pharmaceuticals plant in southwest Miami, scientists and technicians use highly specialized machinery to blend prescription medications and adhesives to make layered transdermal patches...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory...
View ArticleMenopause Drugs from Depomed, Hisamitsu Offer Benefits
Drugs developed for menopausal hot flashes by Depomed Inc. (DEPO) and Hisamitsu Pharmaceutical Co. (4530) are effective, according to staff reviewers at the Food and Drug Administration. While...
View ArticleNew test suggests antidepressant Paxil may promote breast cancer
A team of researchers from the City of Hope in Duarte has developed a speedy way to identify drugs and chemicals that can disrupt the balance of sex hormones in human beings and influence the...
View ArticleNew test suggests antidepressant Paxil may promote breast cancer
A team of researchers from the City of Hope in Duarte, Calif., has developed a speedy way to identify drugs and chemicals that can disrupt the balance of sex hormones in human beings and influence the...
View ArticleFDA approves first nonhormonal drug for hot flashes
Published July 01, 2013The Wall Street Journal The Food and Drug Administration Friday approved the first nonhormonal drug designed to treat hot flashes, one of the most bothersome symptoms of...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee...
View Article